Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

These promising results have positioned Gubra favorably in the competitive landscape of obesity treatments, potentially affecting companies like Zealand Pharma, which is also involved in metabolic ...

And Big Pharmas are making bigger moves now too. Last week, Roche announced a deal with Zealand Pharma, a Danish biotech with four obesity peptides in development including a differentiated ...

The EU pharma deal worth up to $5.3B to develop Zealand’s (OTCPK:ZLDPF) weight loss candidate petrelintide is the newest partnership to enter the obesity drug market, expected to generate as ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF).

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate, as the two firms seek to ...